Lexicon Pharmaceuticals shares were 21% lower, at $1.14, after the company priced its underwritten public offering of 32 million shares at $1.30 a share. All of the shares are being offered by Lexicon ...

In addition to the shares being sold in the underwritten public offering, Lexicon has agreed to sell, in a concurrent private placement for expected aggregate gross proceeds of approximately $41.1 ...

Lexicon Pharma (LXRX) prices 32M-share offering at $1.30 and $41M+ private placement to fund R&D and working capital—get the key details now.

As of Friday, January 30, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 16.32%, which has investors ...

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On January 14, Citi analyst Yigal Nochomovitz increased the price target for ...

Lexicon Pharmaceuticals, Inc. is downgraded to Hold due to repeated FDA rejections of ZYNQUISTA for T1D and catalysts. Read more on LXRX stock here.

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...

Sanofi has terminated a nearly four-year-old, potentially $1.7 billion-plus collaboration with Lexicon Pharmaceuticals to develop ZynquistaTM (sotagliflozin) for type 1 and type 2 diabetes after the ...

“It's a wonderful morning for Lexicon, our scientists, clinicians and the patients and principal investigators,” summed up CEO and Director Lonnel Coats, as the biotech reported results from a phase 2 ...